Richard Klausner, Director at Juno Therapeutics, Inc. (JUNO), sold 24,000 shares at $42.27 ($1.0M) on 2017-09-07, disclosed to the SEC on 2017-09-08.
Open-market sale of $1.0M JUNO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.27 | 5,449 | $230K | 22.5% |
| 2 | $42.27 | 5,449 | $230K | 22.5% |
| 3 | $42.76 | 5,214 | $223K | 21.8% |
| 4 | $42.76 | 5,214 | $223K | 21.8% |
| 5 | $43.83 | 1,337 | $59K | 5.7% |
| 6 | $43.83 | 1,337 |
| $59K |
| 5.7% |
| Total | $42.66 avg | 24,000 | $1.0M | 100% |
| Filing → |
| LYEL | SELL | 2022-09-27 | $71K | — | Filing → |
| JUNO | SELL | 2018-01-09 | $1.2M | — | Filing → |
| JUNO | SELL | 2017-12-22 | $3.2M | — | Filing → |